Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.65 |
| ▸ | ELOC | Q15369 | 9/20 | 0.61 |
| ▸ | ELOB | Q15370 | 9/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458718 | 1.00 | VHL (0.65) | VHLELOCELOB | |
| SCHEMBL26655061 | 0.92 | VHL (0.66) | VHLELOCELOB | |
| SCHEMBL26655291 | 0.92 | VHL (0.68) | VHLELOCELOB | |
| SCHEMBL30566063 | 0.90 | VHL (0.62) | VHLELOCELOB | |
| SCHEMBL22525483 | 0.90 | VHL (0.62) | VHLELOCELOB | |
| SCHEMBL26648772 | 0.89 | VHL (0.63) | VHLELOCELOB | |
| SCHEMBL21405174 | 0.89 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL23431464 | 0.88 | VHL (0.58) | VHLELOCELOB | |
| SCHEMBL15110424 | 0.88 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL16267420 | 0.88 | VHL (0.60) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| US-10071164-B2 | Estrogen-related receptor alpha based protac compounds and associated methods of use | YALE UNIVERSITY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| EP-2985285-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | Yale University (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| WO-2013106646-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071164-B2 | Estrogen-related receptor alpha based protac compounds and associated methods of use | GPER1, PSMA3, ESR2 | VHL 7/4885ELOC 153/4885ELOB 325/4885 |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | VHL 1/4885ELOC 185/4885ELOB 209/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | VHL 1/4885ELOC 190/4885ELOB 241/4885 |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | VHL 2/4885ELOC 211/4885ELOB 249/4885 |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | GPER1, PSMA3, ESR2 | VHL 7/4885ELOC 153/4885ELOB 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.